Several genes that contain the PR (PRDI-BF1 and RIZ) domain have been linked with human cancers. We describe here a new PR-domain-containing gene designated as PRDM5 (PFM2). A PRDM5 cDNA was isolated based on its homology to the PR domain of RIZ1 (PRDM2). The gene encodes an open reading frame of 630 amino acids and contains a PR domain in the NH-terminal region followed by 16 zinc finger motifs. Radiation hybrid analysis mapped PRDM5 to human chromosome 4q26, a region thought to harbor tumor suppressor genes for breast, ovarian, liver, lung, colon, and other cancers. The gene has a CpG island promoter and is silenced in human breast, ovarian, and liver cancers. A recombinant adenovirus expressing PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis.
Introduction
The PR domain was first noted for the homologous B130 aa region shared between RIZ1 (PRDM2) that encodes an Rb-binding protein and the PRDI-BF1/ BLIMP1 (PRDM1) transcription repressor of c-Myc that promotes B-lymphocyte maturation (Keller and Maniatis, 1991; Huang, 1994; Turner et al., 1994; Buyse et al., 1995; Lin et al., 1997) . Both PRDM2 and PRDM1 have growth arrest and proapoptotic activities He et al., 1998) . Deficiency in the PR-domain of PRDM2 causes tumor susceptibility in mice and mutations in this domain are present in human cancers (Steele-Perkins et al., 2001; . The MDS1-EVI1 (PRDM3) gene is commonly mutated in myeloid leukemia and also contains a PR domain (Fears et al., 1996) . The PRDM4 (PFM1) gene was cloned based on its homology to the PR domain, and is located at a tumor suppressor locus on 12q23-q24 (Yang and Huang, 1999) . The rat homolog of PRDM4 was independently cloned through its ability to bind to the p75NGF receptor (Chittka and Chao, 1999) . Overexpression of PRDM4 inhibits DNA synthesis (Chittka and Chao, 1999) . Thus, all presently known PRdomain-containing genes have growth suppressive activities.
The PR domain is related to the SET (Suvar3-9, Enhancer-of-zeste, Trithorax) domain that is commonly present in chromatin-associated proteins involved in euand heterchromatin-mediated gene expression . The PR/SET domain is evolutionarily conserved from yeast to mammals and has proteinbinding interface activities (Cardoso et al., 1998; Cui et al., 1998; Huang et al., 1998; Rozenblatt-Rosen et al., 1998) . The PR domain can be easily distinguished from SET based on sequence homology. The identitiy is typically B45% among PR genes and B50% among SET genes but is B20% between PR and SET genes. The PR domain is primarily present in the C2-H2 type of zinc finger proteins whereas the SET domain is infrequently found in such proteins. The SET domain is related to plant lysine methyltranferases (Schultz et al., 2000) and has histone methyltransferase activities (Rea et al., 2000) . Several SET proteins are mutated or inactivated in human cancers (Huang, 2002; Schneider et al., 2002; , and mutation in the SET protein Suv39H1 causes tumor formation in mice (Peters et al., 2001) . Thus, SET domain proteins have growth or tumor suppressive properties, similar to PR domain proteins, which is consistent with the sequence similarity between these domains.
There are B20 PR domain genes and B30 SET domain genes in humans (Huang, 2002) . Many of these genes have yet to be studied with regard to human cancers. Here we describe the characterization of PRDM5, a novel PR-domain-containing zinc finger gene. We show that this gene is silenced in human cancers and has growth suppressive activities.
Results

PRDM5 (PFM2) gene structure, expression, and chromosomal location
Analysis of the EST database allowed us to identify an EST clone that contains a novel PR domain. Sequence analysis of overlapping EST cDNA clones allowed the assembly of a contiguous cDNA sequence of 2.348 kb encoding an open reading frame of 630 amino acids ( Figure 1a , Genbank accession number AF272897). The open reading frame contains an intact PR domain at the NH-terminus followed by 16 zinc finger domains. This gene was termed PFM2 (gene symbol PRDM5). The cDNA appears to be full length because the putative ATG start codon is preceded by an in-frame stop codon. The complete genomic DNA sequence of PRDM5 gene is also available at the Genbank. This shows a total of 17 exons. The PR domain consists of three exons. By Northern blot analysis, a PRDM5 message of 2.3 kb was detected in colon and ovary, and less strongly in other tissues (Figure 1b ). An abundant mRNA species of 6.0 kb appeared to be specifically expressed in the ovary.
To map the chromosomal location of PRDM5, the Stanford radiation hybrid panel was screened by a pair of PCR primers that amplifies PRDM5 gene. This mapped PRDM5 to within 420 kb from the marker SHGC4-1184 on 4q25-q26.
Identification of a CpG island promoter of PRDM5
The genomic sequence of the whole PRDM5 gene is available in the genome database, from which we have identified a GC-rich region next to the most 5 0 -end or exon 1 of PRDM5 cDNA (Figure 2a ). This region is 391 bp long (nt 151-541 in Figure 2a ) with classical features of a CpG island (CpG ratio ¼ 0.89; CG:GC ratio ¼ 0.87; GC content ¼ 72.1%) (Bird, 1987; Gardiner-Garden and Frommer, 1987) . Since nearly half of all human genes have CpG islands as promoters, we examined whether the PRDM5 CpG island contains promoter activity. A PCR fragment (primers 2.54 and 2.53) of 0.45 kb containing part of this island was cloned into a promoter reporter plasmid pGL3Basic (Figure 2b ). When transfected into 293 cells, promoter activity was observed for the PRDM5-promoter/reporter construct pGLF2P54 (Figure 2c,d) . Therefore, the CpG island at the 5 0 -end of PRDM5 gene functions as a promoter.
PRDM5 gene silencing in human cancers
To study whether PRDM5 gene may be abnormally expressed in human cancer, we performed RT-PCR analysis. PRDM5 expression was reduced or nondetectable in four of 10 breast cancer-cell lines, five of eight hepatoma cell lines, and three of seven ovarian cancer cell line (Figure 3a-c) . To determine whether DNA methylation plays a role in silencing PRDM5 gene expression, we investigated whether PRDM5 expression can be activated by 5-azacytidine, an inhibitor of DNA methylation. MDAH2774 ovarian cancer cells and MB435 breast cancer cells were treated for 3 days with 2.0 mM 5-azacytidine. By RT-PCR analysis, 5-aza-C treatment reactivated PRDM5 expression ( Figure 3d ). This result suggests a probable role of DNA methylation in silencing PRDM5 gene expression.
To study whether decreased expression is linked with promoter CpG island methylation, genomic DNA was isolated from cancer cells and treated with sodium bisulfite. Bisulfite-treated DNA was next analyzed by sequencing and methylation specific PCR (Frommer et al., 1992; Clark et al., 1994; Herman et al., 1996) . The bisulfite genomic sequencing technique allows methylated cytosines to be distinguished through their resistance to bisulfite-mediated deamination; unmethylated cytosines are converted to uridine by bisulfite. The sequence under investigation is then amplified by PCR to yield a product in which all uracil and thymine residues have been amplified as thymine and only 5-methylcytosine residues have been amplified as cytosine. The PCR products can then be cloned and sequenced. We used the primer set 2.63 MF and 2.63 MR to amplify the bisulfite-treated genomic DNA. The PCR products were cloned and 11 individual clones were sequenced. As shown in Figure 4 , a majority of the 17 CpGs within the primer set were methylated in MB435 breast cancer cells and Ha22 T liver cancer cells. Both cell lines lacked PRDM5 mRNA expression.
We developed a methylation-specific PCR (MSP) assay to distinguish methylated and unmethylated DNA. To establish the specificity of our PCR primers, we used plasmid DNA containing PRDM5 genomic DNA before and after treatment with Sss I DNA PRDM5 silencing in human cancers Q Deng and S Huang methylase as controls. This enzyme methylates all CpG cytosines. We confirmed that the primer pair specific for methylated sequences generated a PCR product only with methylated DNA but not with unmethylated DNA, while the primer pair specific for nonmethylated sequences generated a PCR product only with unmethylated DNA (not shown). We also made sure that none of the primer pairs generated any PCR products using nonbisulfite-treated DNA. As shown in Figure 5 , methylation of PRDM5 promoter CpG island was found in breast cancer cell lines (Figure 5a ), hepatoma cell lines (Figure 5b ), ovarian cancer cell lines (Figure 5c ), breast cancer tissues (Figure 5d ), and liver cancer tissues (Figure 5d ). Methylation was not found for three normal matched breast tissues (Figure 5d ) and three normal matched liver tissues (Figure 5d ). We also determined the mRNA expression status of the normal and matched tumor tissues whose methylation status has been determined in Figure 5d . We found reduced or absent mRNA levels in tumors with methylation compared to normal matched tissues (Figure 5e,d) . As some tumor tissues are likely to have infiltrates of normal cells, the lower amount of methylation and mRNA expression in some of these tumors may come from contaminating normal cells. As summarized in Table 1 , methylation was correlated with reduced mRNA expression. Methylation was found for 21 of 40 (53%) breast cancer tissues and 19 of 36 (53%) liver cancer tissues, but was not found in three matched normal breast tissues and three matched normal liver PRDM5 silencing in human cancers Q Deng and S Huang tissues. We evaluated the DNA methylation changes in the tumors and the clinical data obtained from these patients. We found no correlation between methylation and any of the clinicopathological characteristics of the patients (Tables 2 and 3 ). Methylation appears to be more common in high-grade tumors of both liver and breast, but the trend is not statistically significant. We also used MSP assay to test whether demethylation might be induced by 5-aza-C treatment, which may correlate with reactivation of PRDM5 expression in MDAH2774 and MB435 cells. As shown in Figure 5f , 5-aza-C treatment led to an increase in the proportion of unmethylated DNA versus methylated DNA.
PRDM5 expression causes cell cycle arrest
To study PRDM5 protein function, we generated a recombinant adenovirus AdPR5. Immunoblot analysis of infected cells showed a PRDM5-specific band migrating at the 70 kDa position (Figure 6a ), consistent with predicted molecular weight. Immunostaining of infected cells showed nuclear expression, suggesting that PRDM5 is a nuclear protein (Figure 6b ). We next examined the cell cycle profiles of infected cells. As shown in Figure 6c , overexpression of PRDM5 caused an increase in the number of cells at G2/M phase and apoptotic phase in MDAH2774 and BG1 ovarian cancer cell lines, in MB435 breast cancer cell line, and in Ha22T hepatoma cell line. The results suggest that nuclear overexpression of PRDM5 causes G2/M cell cycle arrest and apoptosis.
Discussion
To better understand the role of the PR-domaincontaining gene family in human cancer, we have here characterized a new member of this family, PRDM5. This gene maps to chromosome 4q25-q26. This region is commonly deleted in human breast cancer (Tirkkonen et al., 1997; Schwendel et al., 1998) , ovarian cancer (Sonoda et al., 1997) , lung cancer (Shivapurkar et al., 1999) , hepatoma (Chou et al., 1998; Piao et al., 1998) , cervical cancer (Mitra et al., 1994) , head and neck squamous cell carcinoma (Pershouse et al., 1997) , colon cancer (Arribas et al., 1999) , and oral cancer (Wang et al., 1999) . A candidate for the iris hypoplasia locus also maps on 4q25 (Heon et al., 1995) . Iris hypoplasia is an autosomal dominant disorder that is frequently associated with glaucoma. Our data suggest that PRDM5 may be a candidate for a tumor suppressor located on 4q25-q26. Consistent with location to a common site of chromosomal deletion, PRDM5 gene expression is commonly silenced in several cancer types examined, including breast cancer, ovarian cancer, and liver cancer. This silencing is correlated with CpG island promoter DNA methylation. Our data show that PRDM5 mRNA is at low or undetectable levels in many tumor cell lines. Since our presently available antibody cannot detect endogenous PRDM5 protein, lack of PRDM5 protein expression would have to be presumed based on lack of mRNA expression.
We developed a PCR assay for detecting PRDM5 methylation that could be used for rapid analysis of PRDM5 gene silencing in clinical tumor samples. Our small sample size study here was not informative with regard to a correlation between PRDM5 gene silencing and specific stages of cancer progression. Future studies will be required to address whether PRDM5 gene silencing may be a useful marker in cancer diagnosis and prognosis.
Complete DNA methylation was correlated with lack of mRNA expression. However, we notice that partial DNA methylation was correlated with undectable mRNA in some cell lines but not in others. We speculate that there may be other mechanisms that are involved in PRDM5 gene silencing. Such mechanisms may include DNA methylation in other promoter regions not covered by our present PCR primer set, histone methylation, and mutations in promoter sequences.
Gene silencing is a common mechanism for inactivating the PR-domain-containing tumor suppressor gene RIZ1 (PRDM2) (Du et al., 2001) . PRDM5 is also similar to RIZ1 in having G2/M arrest and proapoptotic functions. It remains to be determined whether such a Samples that showed partial methylation are also included. Samples that showed partial methylation are also included.
PRDM5 silencing in human cancers Q Deng and S Huang
function is not related to protein overexpression. Owing to the cytotoxic effects of 5-aza-C and the non-genespecific nature of its effect in reactivation of silenced genes, reactivation of PRDM5 expression by 5-aza-C cannot be used to examine the effects of endogenous expression of PRDM5 on cell cycle and apoptosis. Nonetheless, the data show that PRDM5 has growth suppressive functions when overexpressed, which is similar to many known tumor suppressor genes. Our data provide new evidence for the suggestion that the PR domain defines a family of growth/tumor suppressive genes (Jiang and Huang, 2000; Huang, 2002; . Future biochemical studies are needed to understand the biological functions of PRDM5. The presence of PR domain and zinc fingers and the nuclear localization suggests that PRDM5 may function as a DNA binding protein involved in chromatin methylation and transcriptional control. Consistent with this, overexpressed PRDM5 is located in the nuclei. Owing to the generally low level expression of endogenous PRDM5 protein or the limited affinity of the presently available antibody against PRDM5, we cannot determine whether endogenous PRDM5 protein is also a nuclear protein.
Histone methyltransferases have recently attracted wide interest. The discovery of these enzymes in tumor suppression has broad implications on the mechanisms of carcinogenesis. It provides a novel molecular pathway on how abnormal diet causes one-third of cancer deaths in the US (Huang, 2002; . As methyltransferases require a methyl donor for activity, a deficiency in dietary methyl donors may cause cancer by inactivating the enzyme activity of histone methyltransferase class tumor suppressor genes. Since the number of PR/SET genes is large (B50), it is important to determine which one of these genes are tumor suppressors. A complete profile of PR/SET genes in cancer will not only provide a better understanding of mechanisms of carcinogenesis but will also facilitate the development of cancer therapeutic strategies based on histone methyltransferases. The discovery of additional tumor suppressor genes such as PRDM5 within the superfamily of PR/SET genes represents an important step toward a full description of histone methyltransferases in cancer.
Materials and methods
Cell lines and tissues
We obtained cancer cell lines from the American Type Culture Collection (ATCC). Human cancer cell lines were grown in Dulbecco's modified Eagle medium (DMEM) plus 10% fetal calf serum. Genomic DNAs from breast cancer and liver cancer have been described previously (Fang et al., 2000 . Additionally, some of the matched normal and tumor 
PRDM5 cDNA cloning
An EST sequence (1467290, Accession number AA884744) was identified, which shows homology to the RIZ1 PR domain. Sequence analysis of this and other overlapping EST clones and RACE PCR cloning allowed us to assemble a contiguous cDNA sequence. Full-length cDNA was cloned by assembling overlapping EST clones and RACE PCR clones.
To express PRDM5 protein in bacteria, we made the construct pQEPR11 that expresses the PR domain region of PRDM5 (amino acids 1-165) by PCR cloning the cDNA into the His-tag vector pQE30 at the BamH1 þ HindIII sites. The PCR primers used are 2.38 (5 0 -G ATC GGA TCC AAA ATG CTG GGC ATG TAC) and 2.39 (5 0 -C ATG AAG CTT ATA GTC CTC TTT ACA GCC). The purified protein was used as antigen for the production of rabbit antiserum PAB264.
We made a mammalian expression construct pCF2-7 expressing a Flag-tagged (at the C-terminus) PRDM5 protein, by cloning the full-length cDNA into the BamH1 and Sal1 sites of the vector pCMVTag4A (Stratagene, San Diego, CA, USA). We also made the construct pCF2-W3 expressing a non-tagged PRDM5 protein by introducing a stop codon just before the tag in pCF2-7. An adenovirus construct pAdF2 was made by cloning the cDNA from pCF2-W3 into the BamH1 þ Sal1 sites of the adenovirus vector pACSR. Adenovirus was then made by cotransfecting into 293 cells pAdF2 and the virus packaging plasmid pJM17, and adenovirus purification was as described previously (He et al., 1998) .
PRDM5 promoter cloning
We subcloned a fragment of the CpG island, amplified using human genomic DNA and primer sets 2.54. (5 0 -TCC TAG ACC GCA GGG TTC GTT C); and 2.53 (5 0 -CCG GAT CCG TTC CTG CCA TTC). To test for promoter activity, we cloned the PCR fragment into the luciferase reporter vector pGL3basic (Promega, WI, USA). The plasmid pGLF2P54 contains a 0.45 kb fragment PRDM5 promoter. pGL3control (Promega) containing SV40 promoter and enhancer was used as positive control. Plasmid DNAs were transfected into human kidney 293 cells by standard calcium phosphate procedure and luciferase activity was determined as described previously (Liu et al., 1997; Xie et al., 1997) . The plasmid pCMVb-gal was cotransfected to serve as control for transfection efficiency and promoter activity was adjusted for b-gal activity.
Chromosomal mapping
The Stanford TNG radiation hybrid panel was screened by a pair of PCR primers that amplifies PRDM5 gene. The primers were 2.12 (5 0 -ctc taa gca cct ttg ctc tg); and 2.6 (5 0 -CAT GAG ATA TTT GAT TGT CAA GAA). PCR result was used to query the Standford Human Genome Center RH server.
Gene expression analysis
Total RNAs were isolated from cell lines and tumor tissues and matched normal tissues and were used as templates for RT-PCR analysis as described previously (He et al.,. 1998; Jiang et al., 1999) . Briefly, reverse transcription was performed using M-MLV reverse transcriptase (NEB) and random oligonucleotide. The first-strand cDNA sample was then amplified using 2.15 (5 0 -GGT GAA AAG TTC GGA CCC TTT); and 2.18 (5 0 -TGC CCG CTG TTG ATT GTC TTC). The primers for amplification of human b-actin are 5 0 -GTG GGG CGC CCC AGG CAC CA-3 0 and 5 0 -CTCCTTAATGT-CACGCACGATTTC-3 0 . PCR reactions were run for 30 cycles. The PCR products were analysed by gel electrophoresis followed by ethidium bromide staining.
DNA methylation analysis
Sequence analysis of genomic DNA templates treated with bisulfite was performed according to the procedure described by Frommer et al. (1992) and modified by Clark et al. (1994) . Briefly, genomic DNAs from tumor tissues and cell lines (50 ng) were treated with sodium bisulfite and treated DNA was purified using the Wizard column (Promega, WI, USA). For DNA sequencing analysis, the DNA was used for PCR by the primer sets 2.63MF (5 0 -GGC GGG AAC GTA CGT CGT CGC GTC G); and 2.63MR (5 0 -CGC GAA CCT AAA CGC TAC GAA CGC CG). The PCR products were subcloned into pCR script cloning vector (Invitrogen) and individual clones were subjected to DNA sequencing analysis.
Bisulfite-treated DNA was also used for MSP analysis (Herman et al., 1996) . We generated PCR primers that distinguish between bisufite-modified and unmodified cytosines in the PRDM5 CpG island. To amplify methylated DNA, we used the primer sets 2.63MF and 2.63MR. To amplify unmethylated DNA, we used the primer sets 2.64UF (5 0 -GGA TAA AGG TGG GAA TGT ATG TTG TTG TGT); and 2.64UR (5 0 -ACT CAA CCC CTC CTC ATC CCA AAT CA).
5-Aza-2
0 -cytidine treatment
Cancer cells (5 Â 10 6 cells ) were grown for 4 days in the presence of various concentrations of 5-aza-2 0 -cytidine (5-Aza-C). Total RNA was isolated and used for RT-PCR analysis as described above. Genomic DNAs were isolated from treated and nontreated cells and used for MSP assays as described above.
Protein expression and cell cycle analysis
Cancer cells were infected with AdPR5 virus or control virus AdNull. At 48 h postinfection, cell extracts were prepared for immunoblot analysis. Cells were stained with anti-PRDM5 antibody PAB264 and DAPI (4 0 -6-diamidino-2-phenylindole hydrochloride) to determine cellular localization of PRDM5. Cells were also processed for cell cycle profile analysis by FACScan as described previously (He et al., 1998) .
